AlphAIalphai — Financial news for AI agents
investing.comAUG 44 min read$HRMY

Oppenheimer lowers Harmony Biosciences stock price target on model updates

Oppenheimer cut its Harmony Biosciences (NASDAQ:HRMY) price target to $70 from $85 but kept an Outperform rating after model updates. Harmony reported Q2 2026 Wakix net sales of $261.3M (+30% YoY) and reaffirmed full-year guidance of $1.00B to $1.04B. Oppenheimer cited new Phase 1 data for BP-205 and expects further Phase 1 readouts in Q4 2026 and early 2027.

Original reporting
investing.com
Published Aug 4, 2026, 7:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 5:21 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$HRMY
Neutral
medium confidence
Mentioned
$HRMY · $OPY
Relevance
5/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$HRMYNeutralLow
01

Why it matters

The immediate tradable element is the analyst price-target reduction, while the fundamental trajectory hinges on upcoming BP-205 dose-escalation and volunteer studies and the Oct 22, 2026 Wakix IP resolution timeline.

02

Market read

A concrete sell-side PT cut tied to updated modeling assumptions, occurring alongside a Q2 beat and reaffirmed guidance, creates a mixed but tradable sentiment signal.

03

What to watch

Key upcoming catalysts are scheduled for Q4 2026 (multiple ascending dose) and early 2027 (sleep-deprived volunteer data), plus Wakix IP court proceedings on Oct 22, 2026.

Relevance 5/10Novelty 4/10Timing: today, pre-market/early session analyst note impact

Background

Oppenheimer updated its Harmony Biosciences model using actual results and adjustments, alongside newly cited Phase 1 BP-205 data.

Company-level read

Ticker impact

$HRMYNeutralMedium confidence
Context

Oppenheimer cut Harmony Biosciences' price target to $70 from $85 while citing updated model inputs and Phase 1 BP-205 data.

Expected impact

Likely modest downside bias versus prior target, with follow-through dependent on Q4 2026 Phase 1 multiple-ascending-dose readout.

Evidence & confidence

The article provides a concrete PT change and specific clinical/data milestones, but it is still an analyst model update rather than a new company disclosure.

Market effects

Sector

Reinforces that orexin-2/sleep-disorder biotech valuation is sensitive to early clinical dose-response assumptions and IP litigation timelines.

Regional

No clear regional spillover beyond US small/mid-cap biotech sentiment.

Global

Limited, as the catalyst is company-specific clinical and analyst modeling.

Counterpoint

What could challenge this read

Despite the PT cut, the company beat Q2 expectations, reaffirmed full-year revenue guidance, and reported no serious safety signals in early BP-205 Phase 1 data.

Key entities

  • public_company
    Harmony Biosciences Holdings Inc.

    NASDAQ-listed biotech; Oppenheimer lowered its price target and cited BP-205 Phase 1 updates while the company reaffirmed 2026 guidance.

  • drug_program
    BP-205

    Orexin-2 agonist in Phase 1 for social anxiety disorder; early data cited as supporting once-daily dosing and selectivity.

  • product
    Wakix

    Primary revenue driver; full-year 2026 guidance reaffirmed and IP court proceedings scheduled for Oct 22, 2026.

Read at source← All news

Related articles

SEP 3
$HRMYHighAI 8/10

Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

Harmony Biosciences (HRMY) stock rose 12.1% since last earnings. The company expects multiple clinical trial data in 2026-2027, including for pitolisant GR and epilepsy treatments. HRMY reaffirmed 2026 revenue guidance of $1B-$1.04B, with Q2 revenues up 21% sequentially. Analysts have upwardly revised estimates, and HRMY has an aggregate VGM Score of A.

finance.yahoo.com2 min
SEP 2
$SPCXHighAI 8/10

SPCX Stock Jumps as SpaceX Price Target Raised by Oppenheimer

SPCX stock rose 0.50% premarket after Oppenheimer raised its price target to $280, citing SpaceX's AI platform and higher revenue estimates. Oppenheimer maintained an 'outperform' rating, and other firms like Bernstein and JPMorgan also issued positive ratings. SpaceX's Q1 revenue grew 92% to $7.81B, with a net loss of $541M. The stock has gained over 30% in a month, trading at $142.97.

coingape.com2 min
AUG 29
$DPZHigh

Domino’s Pizza (DPZ) Rallies As Oppenheimer Backs Upside

Domino’s Pizza (DPZ) stock rose 5.4% after strong earnings and positive analyst sentiment. Oppenheimer set a $415 target, citing resilient fundamentals and growth catalysts. DPZ trades around $350, with support at $332 and resistance at $380. The company reports $4.94B revenue, 40% gross margin, and 19% EBIT margin.

timothysykes.com2 min
AUG 28
$DPZHighAI 8/10

Domino’s Pizza DPZ Surges As Oppenheimer Sticks With Outperform Call

Domino’s Pizza (DPZ) stock rose 5.4% following strong earnings and upbeat same-store sales growth. Analysts highlight its strong unit economics, with ROA above 30%, EBIT margin ~19%, and solid free cash flow. Oppenheimer maintains an outperform rating with a $415 target, citing quality growth and reasonable valuation at ~19.5x EPS. Technical analysis points to support near $332 and resistance at $355.

stockstotrade.com2 min
AUG 28
$OPYHigh

Why is Oppenheimer Holdings stock gaining over 2% today?

Oppenheimer Holdings stock rose 2.7% in pre-market trading to $123.25, surpassing its 52-week high, as the company distributed a $0.20 per share dividend. This follows strong Q2 2026 earnings, with revenue up 21.9% YoY to $454.9M and adjusted EPS at $4.27. Client assets under management reached a record $59.4B. The stock's technical breakout and positive fundamentals drove the gain, independent of broader market trends.

investing.com1 min